| ☆共ＪＢＮ 外１２３５（産業、医療）（０４・１２・７） 【産業業担当デスク殿】１７３８９ ◎メデックス買収で合意 英スミスグループ 【カールズバッド（米カリフォルニア州）６日ＰＲＮ＝共同ＪＢＮ】米メデックス（Me dex, Inc.）は６日、英国のスミスグループ（Smiths Group plc）が株式非公開会社のメ デックスを買収することに合意したと発表した。これで救急医療に使われる機器でのスミ スメディカルの世界的なプレゼンスが大幅に拡大する。スミスメディカルとメデックスは ともに成長企業で、世界的に医療機器を開発、製造、販売しており、この買収によってス ミスは両社製品の売上高成長が加速すると期待している。 買収完了は新年の見込みで、規制当局の承認が必要。 メデックス製品は、感染防止部門、集中治療室、麻酔、呼吸器部門など、顧客による重 要なのコールポイント（緊急呼び出し地点）でスミスのプレゼンスを拡大することになる 。地理的には、メデックスの売り上げの３分の２は北米で、すでに国際市場でプレゼンス の確立に成功しているものの、スミスメディカル・インターナショナルを通じてこれらの 市場への参入をさらに拡大できる機会はかなり大きい。 メデックスの製品はスミスの領域と高度に補完性があり、病院と代替医療施設の同じ顧 客基盤に販売している。同社のドミニック・アリーナ社長兼最高経営責任者（ＣＥＯ）は 「この買収で独立企業としては提供できないような幅広い製品、付加価値サービスをわが 社の顧客に提供できる」と述べた。 メデックスの売り上げの３分の２はプロテクティブ（ＰＲＯＴＥＣＴＩＶ、登録商標） 、アキュバンス（ＡＣＵＶＡＮＣＥ、登録商標）など、市場リーダー級と認められている 静脈カテーテルが占めている。これらの製品は使用後の針先による偶発的なけがを防ぐよ うに設計されており、市場ではスミスのニードルプロ（Ｎｅｅｄｌｅ−Ｐｒｏ、登録商標 ）安全機器類と並ぶ。またメデックスは医療過誤探知機能を組み込んだ先進的な洗浄ポン プ（医療安全ソフトウエアＰｈａｒｍＧｕａｒｄ、商標、搭載のメディフュージョン３５ ００、登録商標など）を製造しているが、スミスは歩行可能患者用注入ポンプの供給では 世界市場で有力な会社である。 メデックス買収の利点についてスミスメディカルのローレンス・キネット取締役は「ス ミスメディカルにとって大きなチャンスだ。年間売上高は１２億５０００万ドルに近づき 、製品の幅の拡大によって競争力は強化される。救急医療、特に安全機器でのプレゼンス が増大し、世界的なネットワークを利用してメデックスの製品領域を強い需要のある新市 場に持ち込める。ドミニック・アリーナ氏の率いるメデックスの上級経営チームは買収完 了後少なくとも１年間はその地位に留まることに同意した。メデックスがスミスグループ の一部になれば、融合チームは早急に販売、事業、管理面の相乗効果を生み出すだろう」 と語った。 アリーナ社長はさらに「統合会社の成功は実際は顧客と従業員の成功になるだろう。統 合から利益を受け、統合が提供する新たなチャンスを共有できるからだ」と述べた。 ▽メデックスについて さまざまな治療法、診断法、長期治療法の急性と代替医療で使われる救急医療、代替医 療製品を世界的に製造、販売している。世界的な販売力と供給ネットワークを通じて、７ ５カ国以上で約５５００の病院、健康管理システム、代替健康管理機関に救急医療システ ムと製品を販売している。本社は米カリフォルニア州カールズバッド。従業員は世界で約 ２０００人。詳しい情報はhttp://www.medex.com へ。 ▽スミスメディカルについて スミスグループ（本社ロンドン）の１部門で、救急、集中治療、手術、回復期の術後管 理、一連の家庭注入療法で使われる機器の有力供給会社。２００４年７月３１日までの１ 年間の売上高は４億８８００万ポンド（８億５３００万ドル）。スミスグループは医療、 航空宇宙、探知、特殊エンジニアリングの分野で先進的な技術ソリューションを提供して いる。同グループはロンドン証券取引所に上場されており（「ＳＭＩＮ」）２００４年７ 月３１日までの１年間の売上高は２７億ポンド（４７億ドル）、通常活動による税引き前 利益は３億５０００万ポンド（６億１３００万ドル）。営業利益の６０％近くは米国から のもので、全体で２万７０００人の従業員のうち１万３０００人は米国で働いている。 （了） ▽問い合わせ先 Gregory Aranaga, Director, Corporate Communications, +1-760-602 4455, garanaga@medex.com Web site: http://www.medex.com Medex Announces Acquisiton by Smiths Group CARLSBAD, Calif., Dec. 6 /PRN=KYODO JBN/ -- Acquisition Creates Global Market Share Leader in Critical Care Medex, Inc. today announced that Smiths Group plc, a UK based manufacturer has agreed to acquire privately-held Medex in a transaction which will greatly enhance the global presence of Smiths Medical for devices used in critical care. Smiths Medical and Medex are both growing businesses that develop, manufacture and market medical devices around the world, and through this transaction Smiths expects to accelerate sales growth of both Smiths Medical and Medex products. Completion of this acquisition, expected in the New Year, is subject to regulatory approval. Medex products will increase Smiths' presence at a number of important customer call points, especially infection control departments, intensive care units, anesthesia and respiratory departments. Geographically, two-thirds of Medex's sales are made in North America and, while the company has already successfully established a presence in International Markets, there is considerable opportunity to further expand into those markets through Smiths Medical International. Medex products are highly complementary with the Smiths Medical range, selling to the same customer base in hospitals and alternate care facilities. Dominick Arena, president and chief executive officer of Medex, stated "The acquisition provides our customers with the full breadth of products and value-added services that as independent companies we could not provide." Two-thirds of Medex's sales are of intravenous catheters such as PROTECTIV(R) and ACUVANCE(R), recognized as among the market leaders. These products are designed to prevent accidental injuries caused by needle "sharps" which remain exposed after use, and are aligned in the market with the Smiths Needle-Pro(R) range of safety devices. Medex also makes advanced syringe pumps (such as the Medfusion(TM) 3500 with PharmGuard(TM) Medication Safety Software) which incorporate medication error detection, while Smiths is the leading supplier of ambulatory infusion pumps in the worldwide market. Commenting on the benefit of bringing Medex into Smiths Medical, Lawrence Kinet, board member for the division said, "This is a great opportunity for Smiths Medical. Annual sales will be approaching $1.25 billion, and we become more competitive by offering a wider range of products. We'll have a greater presence in critical care, especially in safety devices, and we can use our global network to take the Medex range into new markets where we know there is strong demand. "The Medex senior management team, led by Dominick Arena, has agreed to remain in place for at least one year following completion of the transaction. Integration teams will deliver sales, operational and administration synergies quickly, once Medex becomes part of Smiths Group. Mr. Arena further added, "The combined company's success will really be the success of our customers and our employees, who will benefit and share in the additional opportunities that this combination provides for them." About Medex Medex is a global manufacturer and marketer of critical care and alternate care medical products used in both acute and alternate care settings for a variety of therapeutic, diagnostic and long-term procedures. Medex markets and sells critical care systems and products to over 5,500 hospitals, health care systems, and alternate healthcare settings in more than 75 countries through a global sales force and distribution network. Headquartered in Carlsbad, California, the Company employs approximately 2,000 people worldwide. For more information, please visit http://www.medex.com. About Smiths Medical Smiths Medical, a division of London based Smiths Group plc, is a leading supplier of devices used during critical and intensive care, surgery, post-operative care during recovery, and in a series of home infusion therapies. For the year ended 31 July 2004 Smiths Medical had sales of pounds Sterling 488m ($853m). Smiths Group offers advanced technology solutions in medical, aerospace, detection, and specialty engineering sectors. Listed on the London Stock Exchange (SMIN), the company recorded sales of pounds Sterling 2.7 billion ($4.7 billion) and pre-tax profit on ordinary activities of pounds Sterling 350m ($613m) for the year ended 31 July 2004. Close to 60% of operating income originates from the United States, where 13,000 of the company's total 27,000 people are employed. Forward-Looking Statements This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. Detailed information about such risk factors is set forth in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update, alter or release publicly any revisions to its forward-looking statements, whether as a result of new information, subsequent events or developments. Contact: Gregory Aranaga Director, Corporate Communications +1 (760) 602 4455 garanaga@medex.com http://www.medex.com SOURCE Medex, Inc. -0- 12/06/2004 /CONTACT: Gregory Aranaga, Director, Corporate Communications, +1-760-602 4455, garanaga@medex.com/ /Web site: http://www.medex.com / |